PHGE Share Price Performance
US$4.62
-5.94 (-56.24%)
97.2% undervalued intrinsic discount
US$165.00
Fair Value
Price US$4.62
AnalystConsensusTarget US$165.00
Fair ValueUS$165.00
Share Pricen/a
BiomX Inc. Stock Price
- 1 Narratives written by author
- 0 Comments on narratives written by author
- 5 Fair Values set on narratives written by author
PHGE Community Narratives
AN
Fair Value US$165 97.2% undervalued intrinsic discount
Regulatory Tailwinds And Antimicrobial Resistance Focus Will Support Long Term Phage Therapy Potential
0users have liked this narrative
0users have commented on this narrative
2users have followed this narrative
Regulatory Tailwinds And Antimicrobial Resistance Focus Will Support Long Term Phage Therapy Potential
Catalysts About BiomX BiomX is a clinical stage company developing precision bacteriophage therapies targeting difficult bacterial infections. What are the underlying business or industry changes driving this perspective?Read more
7
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
2users have followed this narrative
AN
US$165
97.2% undervalued intrinsic discount
Fair Value
Profit Margin
10.89%
Future PE
530.69x
Price in 2029
US$0
Trending Discussion
Recently Updated Narratives
AN
Regulatory Tailwinds And Antimicrobial Resistance Focus Will Support Long Term Phage Therapy Potential
Fair Value: US$165 97.2% undervalued intrinsic discount
2 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
BiomX Inc. Key Details
About PHGE
- Founded
- 2015
- Employees
- 20
- CEO
- WebsiteView website
BiomX Inc., a clinical-stage biopharmaceutical company, develops phage-based therapies using natural and engineered phage technologies designed to target and kill specific harmful bacteria associated with chronic diseases. The company’s phage-based therapies include fixed cocktail therapy, which involves developing a single product containing a fixed number of selected phages to cover a range of bacterial strains; and personalized therapy, which involves developing a large library of phages from which single optimal phages are personally matched to treat specific patients. It develops BX011, a fixed multi-phage cocktail, which is in Phase 2a trial for the treatment of diabetic foot infections; and BX211, a phage therapy, which is in Phase 2 trial for the treatment of diabetic foot osteomyelitis. BiomX Inc. was founded in 2015 and is based in Dover, Delaware.
